Description |
AZ'6421 acts as Protcolysis Targeting Chimera (PROTAC) to selectively degrade estrogen receptor alpha. AZ'6421 has a potent anti-tumour effect to inhibit the uncontrolled cellular proliferation which arises from malignant disease. AZ'6421 can be used for the research of cancer such as breast cancer[1].
|
Related Catalog |
|
Target |
IC50: 0.6 nM (ER binding); 0.4 nM (ER degradation)[1]
|
In Vitro |
AZ'6421 (example 72) exhibits anti-tumour activity via the ability to degrade the estrogen receptor in a number of different breast cancer cell-lines (MCF-7, CAMA-I, and BT474)[1]. AZ'6421 (0.3 μM) has ER binding and ER degradation with IC50 values of 0.6 nM and 0.4 nM, respectively in MCF-7 cell lines[1].
|
References |
[1]. Bin Yang, et al. Compounds and their use in treating cancer. Patent WO2019123367A1.
|